SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.

The Sox4 transcription factor mediates early B-cell differentiation. Compared with normal pre-B cells, SOX4 promoter regions in Ph(+) ALL cells are significantly hypomethylated. Loss and gain-of-function experiments identified Sox4 as a critical activator of PI3K/AKT and MAPK signaling in ALL cells. ChIP experiments confirmed that SOX4 binds to and transcriptionally activates promoters of multiple components within the PI3K/AKT and MAPK signaling pathways. Cre-mediated deletion of Sox4 had little effect on normal pre-B cells but compromised proliferation and viability of leukemia cells, which was rescued by BCL2L1 and constitutively active AKT and p110 PI3K. Consistent with these findings, high levels of SOX4 expression in ALL cells at the time of diagnosis predicted poor outcome in a pediatric clinical trial (COG P9906). Collectively, these studies identify SOX4 as a central mediator of oncogenic PI3K/AKT and MAPK signaling in ALL.

[1]  M. Loh,et al.  Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. , 2012, Blood.

[2]  N. Jenkins,et al.  Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. , 2011, Blood.

[3]  A. Melnick,et al.  Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. , 2011, Blood.

[4]  Sebastian Herzog,et al.  BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition , 2011, Nature.

[5]  Alexander D. MacKerell,et al.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. , 2010, Cancer cell.

[6]  J. Cigudosa,et al.  The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. , 2009, Human molecular genetics.

[7]  Colleen D. McCabe,et al.  Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. , 2009, Cancer research.

[8]  Jorng-Tzong Horng,et al.  Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma , 2008, Oncogene.

[9]  K. Shokat,et al.  Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. , 2008, The Journal of clinical investigation.

[10]  Ignacio A. Demarco,et al.  Regulation of B cell fate commitment and immunoglobulin heavy-chain gene rearrangements by Ikaros , 2008, Nature Immunology.

[11]  R. Spang,et al.  Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia , 2006, Clinical Cancer Research.

[12]  V. Lefebvre,et al.  Generation of mice harboring a Sox4 conditional null allele , 2006, Genesis.

[13]  M. Roussel,et al.  Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Pengbo Liu,et al.  Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. , 2006, Cancer research.

[15]  N. Copeland,et al.  Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. , 2006, Blood.

[16]  N. Copeland,et al.  Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. , 2005, Blood.

[17]  Richard A. Flavell,et al.  Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts , 2002, Nature Genetics.

[18]  John Armstrong,et al.  Cytokine-Specific Transcriptional Regulation Through an IL-5Rα Interacting Protein , 2001, Science.

[19]  E. Andreu,et al.  Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL , 2000, The Journal of experimental medicine.

[20]  T. Pawson,et al.  The Carboxyl Terminus of B Class Ephrins Constitutes a PDZ Domain Binding Motif* , 1999, The Journal of Biological Chemistry.

[21]  M. Minden,et al.  An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma , 1997, Oncogene.

[22]  G. Reekmans,et al.  Syntenin, a PDZ protein that binds syndecan cytoplasmic domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Wen-Lin Kuo,et al.  ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis , 1997, Oncogene.

[24]  A. Cumano,et al.  Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4 , 1996, Nature.

[25]  R. Hardy,et al.  Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. , 1996, Immunity.

[26]  F. Finkelman,et al.  bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice , 1996, The Journal of experimental medicine.

[27]  T. Hambuch,et al.  The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Strasser,et al.  Immature surface Ig+ B cells can continue to rearrange kappa and lambda L chain gene loci , 1993, The Journal of experimental medicine.

[29]  H. Clevers,et al.  Sox‐4, an Sry‐like HMG box protein, is a transcriptional activator in lymphocytes. , 1993, The EMBO journal.

[30]  J. Greally,et al.  The HELP assay. , 2009, Methods in molecular biology.

[31]  R. Hardy,et al.  B cell development pathways. , 2001, Annual review of immunology.